Zennadi R[Author] - Search Results

Year	Number of Results
1992	4
1993	3
1997	1
2001	1
2004	1
2006	1
2007	1
2008	2
2011	3
2012	2
2013	2
2014	1
2015	2
2016	2
2019	3
2020	2
2021	0

1

MEK1/2 as a Therapeutic Target in Sickle Cell Disease.

Zennadi R. Zennadi R. Int J Blood Res Disord. 2019;6:38. doi: 10.23937/2469-5696/1410038. Epub 2019 Apr 4. Int J Blood Res Disord. 2019. PMID: 31709379 Free PMC article.

2

Oxidative Stress and Thrombosis during Aging: The Roles of Oxidative Stress in RBCs in Venous Thrombosis.

Wang Q, Zennadi R. Wang Q, et al. Among authors: zennadi r. Int J Mol Sci. 2020 Jun 15;21(12):4259. doi: 10.3390/ijms21124259. Int J Mol Sci. 2020. PMID: 32549393 Free PMC article. Review.

3

Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo.

McMahon TJ, Shan S, Riccio DA, Batchvarova M, Zhu H, Telen MJ, Zennadi R. McMahon TJ, et al. Among authors: zennadi r. Blood Adv. 2019 Sep 10;3(17):2586-2597. doi: 10.1182/bloodadvances.2019031633. Blood Adv. 2019. PMID: 31484636 Free PMC article.

4

Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in vivo.

Thamilarasan M, Estupinan R, Batinic-Haberle I, Zennadi R. Thamilarasan M, et al. Among authors: zennadi r. Blood Adv. 2020 Jun 9;4(11):2372-2386. doi: 10.1182/bloodadvances.2020001642. Blood Adv. 2020. PMID: 32479589 Free PMC article.

5

Disrupting the vicious cycle created by NOX activation in sickle erythrocytes exposed to hypoxia/reoxygenation prevents adhesion and vasoocclusion.

MacKinney A, Woska E, Spasojevic I, Batinic-Haberle I, Zennadi R. MacKinney A, et al. Among authors: zennadi r. Redox Biol. 2019 Jul;25:101097. doi: 10.1016/j.redox.2019.101097. Epub 2019 Jan 11. Redox Biol. 2019. PMID: 30661992 Free PMC article.

6

LW protein: a promiscuous integrin receptor activated by adrenergic signaling.

Delahunty M, Zennadi R, Telen MJ. Delahunty M, et al. Among authors: zennadi r. Transfus Clin Biol. 2006 Mar-Apr;13(1-2):44-9. doi: 10.1016/j.tracli.2006.02.022. Epub 2006 Mar 29. Transfus Clin Biol. 2006. PMID: 16564726 Review.

7

Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.

Telen MJ, Batchvarova M, Shan S, Bovee-Geurts PH, Zennadi R, Leitgeb A, Brock R, Lindgren M. Telen MJ, et al. Among authors: zennadi r. Br J Haematol. 2016 Dec;175(5):935-948. doi: 10.1111/bjh.14303. Epub 2016 Aug 23. Br J Haematol. 2016. PMID: 27549988

8

MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.

Zhao Y, Schwartz EA, Palmer GM, Zennadi R. Zhao Y, et al. Among authors: zennadi r. FASEB J. 2016 Mar;30(3):1171-86. doi: 10.1096/fj.15-278481. Epub 2015 Nov 30. FASEB J. 2016. PMID: 26631480

9

RNA aptamer therapy for vaso-occlusion in sickle cell disease.

Burnette AD, Nimjee SM, Batchvarova M, Zennadi R, Telen MJ, Nishimura J, Sullenger BA. Burnette AD, et al. Among authors: zennadi r. Nucleic Acid Ther. 2011 Aug;21(4):275-83. doi: 10.1089/nat.2010.0270. Epub 2011 Jun 28. Nucleic Acid Ther. 2011. PMID: 21793788

10

Effect of propranolol as antiadhesive therapy in sickle cell disease.

De Castro LM, Zennadi R, Jonassaint JC, Batchvarova M, Telen MJ. De Castro LM, et al. Among authors: zennadi r. Clin Transl Sci. 2012 Dec;5(6):437-44. doi: 10.1111/cts.12005. Epub 2012 Oct 17. Clin Transl Sci. 2012. PMID: 23253664 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results